C. Slaney

发表

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

Paul J Hertzog, Yuan Cao, Thomas Mikeska, 2012, Nature Medicine.

Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies

Scott N. Mueller, M. Kershaw, C. Slaney, 2021, Journal for ImmunoTherapy of Cancer.

Cellular networks controlling T cell persistence in adoptive cell therapy

P. Darcy, P. Beavis, A. Kallies, 2021, Nature Reviews Immunology.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

S. Loi, J. Trapani, P. Darcy, 2017, Cancer research.

Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers

M. Kershaw, C. Slaney, Xin Du, 2021, Immunotherapy advances.

Challenges and Opportunities for Effective Cancer Immunotherapies

M. Kershaw, C. Slaney, 2020, Cancers.

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

J. Rautela, C. Slaney, B. Parker, 2013, Cancer research.

Genome editing provides solution for cell therapy safety and immune tolerance : a guide for a One 4 All pluripotent cell line

S. Loi, J. Trapani, A. Trounson, 2018 .

Enterotoxins can support CAR T cells against solid tumors

Kylie M. Quinn, P. Darcy, M. Kershaw, 2019, Proceedings of the National Academy of Sciences.

Primary and metastatic breast tumors cross-talk to influence immunotherapy responses

S. Keam, P. Darcy, M. Kershaw, 2020, Oncoimmunology.

The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone

P. Hertzog, A. Möller, C. Slaney, 2013, Oncoimmunology.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

S. Loi, P. Darcy, M. Kershaw, 2018, Front. Immunol..

Enhancing chimeric antigen receptor T‐cell immunotherapy against cancer using a nanoemulsion‐based vaccine targeting cross‐presenting dendritic cells

J. Trapani, P. Darcy, Ranjeny Thomas, 2020, Clinical & translational immunology.

A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer

R. Johnstone, P. Darcy, Yuchen Bai, 2021, Clinical Cancer Research.

Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene

J. Schröder, A. Papenfuss, P. Darcy, 2015, PloS one.

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma

G. McArthur, C. Cullinane, K. Sheppard, 2021, Cancers.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3− Cell–Mediated Modulation of CD103+ Dendritic Cells

S. Loi, J. Trapani, P. Darcy, 2018, Cancer Immunology Research.

The Use of Myeloid Suppressor Cells to Inhibit Experimental Autoimmune Encephalomyelitis: a Potential Immunotherapy for Multiple Sclerosis

C. Slaney, 2009 .

Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer

Jian Zhang, C. Slaney, P. Luo, 2020, Journal of thoracic disease.

Glatiramer Acetate Treatment Directly Targets CD11b+Ly6G− Monocytes and Enhances the Suppression of Autoreactive T cells in Experimental Autoimmune Encephalomyelitis

J. Harper, B. Bäckström, C. Slaney, 2011, Scandinavian journal of immunology.

Naïve blood monocytes suppress T‐cell function. A possible mechanism for protection from autoimmunity

J. Harper, A. L. La Flamme, B. Bäckström, 2011, Immunology and cell biology.

Cathepsin B inhibition limits bone metastasis in breast cancer.

Bonnie F. Sloane, M. Bogyo, K. Moin, 2012, Cancer research.

Clinical application of genetically modified T cells in cancer therapy

P. Darcy, M. Kershaw, J. Westwood, 2014, Clinical & translational immunology.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting

D. Tscharke, J. Trapani, S. Rosenberg, 2016, Clinical Cancer Research.

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.

P. Darcy, P. Beavis, M. Kershaw, 2016, Seminars in immunology.

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer

M. Kershaw, C. Slaney, A. Oliver, 2019, Front. Oncol..

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.

P. Darcy, M. Kershaw, Pin Wang, 2018, Cancer discovery.

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

P. Darcy, M. Kershaw, C. Duong, 2015, Molecular immunology.

A modified superantigen rescues Ly6G− CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE

J. Harper, J. Fraser, B. Bäckström, 2013, Autoimmunity.

Cross‐talk between tumors at anatomically distinct sites

J. Trapani, P. Darcy, M. Kershaw, 2020, The FEBS journal.

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

P. Pauwels, P. Darcy, M. Peeters, 2020, Clinical & translational immunology.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

S. Loi, L. Kats, J. Trapani, 2017, The Journal of clinical investigation.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy

J. Whisstock, D. Tscharke, G. Ramm, 2017, Oncotarget.

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

P. Darcy, P. Beavis, M. Kershaw, 2015, Immunotherapy.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Robin L. Anderson, C. Johnstone, Cameron N. Johnstone, 2014, Cancer research.

Therapeutics , Targets , and Chemical Biology Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer

Bonnie F. Sloane, M. Bogyo, K. Moin, 2012 .

Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities

P. Darcy, M. Kershaw, C. Slaney, 2020, Journal of thoracic disease.

Trafficking of T cells into tumors.

P. Darcy, M. Kershaw, Clare Y Slaney, 2014, Cancer research.

Tissue‐specific tumor microenvironments influence responses to immunotherapies

S. Keam, P. Darcy, P. Beavis, 2019, Clinical & translational immunology.

CD73: A potential biomarker for anti-PD-1 therapy

S. Loi, P. Darcy, P. Beavis, 2015, Oncoimmunology.

TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models

J. Desai, J. Trapani, P. Ekert, 2023, Science Translational Medicine.

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer

P. Hertzog, A. Möller, Robin L. Anderson, 2015, Cancer Immunology Research.

Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses

P. Darcy, M. Kershaw, C. Slaney, 2020, Journal of thoracic disease.

Releasing the Brake on Oncolytic Viral Therapy

P. Darcy, C. Slaney, 2015, Clinical Cancer Research.

YBX1 integration of oncogenic PI3K/mTOR signalling regulates the fitness of malignant epithelial cells

S. Jane, S. Stacker, W. Phillips, 2023, Nature Communications.

Editorial: Combining chemo/radio therapy and immunotherapy for cancers—perfect mix of old and new

Jian Zhang, Linlang Guo, C. Slaney, 2023, Frontiers in Immunology.

P059 Tumor cell derived type I IFN stimulates tumor immunosurveillance, suppressing metastasis to bone

P. Hertzog, Robin L. Anderson, J. Rautela, 2012 .

FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

I. Parish, P. Darcy, P. Beavis, 2024, Nature.